Geron Corporation (GERN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Geron Corporation (GERN) closed at USD 1.23 on 2026-10-15, a change of +0 % over the past year, with a market capitalization of USD 751.69M.

Geron Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Geron Corporation key figures

Previous close

USD 1.23 (2026-10-15)

1-year change

+0 %

Market cap

USD 751.69M

Enterprise value

USD 572.99M

P/E ratio (trailing)

-10.64

P/E ratio (forward)

29.25

EPS (trailing)

-0.11

EPS (forward)

0.04

PEG ratio

n/a

Price to book

3.44

Revenue growth

17.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.73

Employees

258

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Geron Corporation and compare it with other stocks.